Medicine volatilization sheet

Abstract

To provide a medicine volatilization sheet such as to be pasted on a user's skin or garment, to be hung from the user's neck, and to be placed on a predetermined place, the medicine volatilization sheet enabling a medicine to be sufficiently volatilized and enabling the user to be inhibited from being in contact with a medicine holding layer containing the medicine.SOLUTION: A medicine volatilization sheet comprising a medicine holding layer containing medicine and a transmission layer provided on one or both sides of the medicine holding layer to transmit the medicine is prepared, the transmission layer having an area covering the medicine holding layer and an area not covering the medicine holding layer, the area covering the medicine holding layer containing photo-curing resin or thermosetting resin.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a drug volatilizing sheet, and more particularly to a drug volatilizing sheet that can be brought into direct or indirect contact with the skin or clothing of a user, worn around the neck, or placed on a predetermined location. [Background technology]

[0002] Conventionally, pest control chemical volatilization sheets have been known that include a pest control layer containing a volatile compound that repels or exterminates pests in order to prevent damage from pests, such as preventing insect bites. Such chemical volatilization sheets are used by being attached to the user's skin or clothing or placed in a specific storage container. The compound, which is the active ingredient, gradually volatilizes from the pest control layer in the sheet, thereby preventing damage from pests by, for example, keeping pests away.

[0003] As such a chemical volatilizing sheet, for example, Patent Document 1 discloses a chemical volatilizing sheet having a chemical retention layer impregnated with at least one of a repellent or an insecticide, a barrier layer provided on one side of the chemical retention layer that is impermeable to the repellent or insecticide, and an adhesive layer provided on the barrier layer on the opposite side of the chemical retention layer and that can adhere to an object to be adhered. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 2019-137668 Summary of the Invention [Problem to be solved by the invention]

[0005] However, in the invention of Patent Document 1, because the user can touch the drug retention layer, there is a risk that, depending on the type of drug, contact may cause symptoms of poisoning, such as discomfort, vomiting, diarrhea, headache, tinnitus, etc. On the other hand, if the user is prevented from touching the drug retention layer to prevent such symptoms of poisoning, there is a contradictory problem in that the drug will not be sufficiently vaporized.

[0006] Therefore, the object of the present invention is to provide a drug-evaporating sheet that allows the drug to be sufficiently evaporated while preventing the user from coming into contact with the drug-containing drug retention layer. [Means for solving the problem]

[0007] That is, the present invention relates to the following chemical volatilizing sheet. [1] A drug volatilization sheet comprising a drug retention layer and a permeable layer that is provided on one or both sides of the drug retention layer and allows the drug to permeate, the permeable layer having an area that covers the drug retention layer (coated area) and an area that does not cover the drug retention layer (uncoated area), and the coated area contains a photo- or thermosetting resin, (100mm 2 The area of the uncoated area per 2 )) / (thickness of the permeable layer (mm))=80 to 350.

[0008] [2] The drug volatilizing sheet according to [1], wherein the thickness of the permeable layer is 0.2 to 2 mm.

[0009] [3] A drug volatilizing sheet described in [1] or [2], wherein the areas of the permeable layer that cover the drug retention layer form an arbitrary pattern together with the uncovered areas, and the ratio of the uncovered areas to the covered areas is 1:0.3 to 50.

[0010] [4] A method for producing a drug volatilizing sheet according to any one of [1] to [3], A manufacturing method comprising the step of forming the transmission layer by printing an ink containing a photo- or thermosetting resin on the drug retention layer. [Effects of the Invention]

[0011] According to the drug volatilization sheet of the present invention, the drug is sufficiently volatilized and the user can be prevented from coming into contact with the drug-containing drug retention layer. [Brief explanation of the drawings]

[0012] [Figure 1] FIG. 1 is a plan view of a drug volatilization sheet according to one embodiment of the present invention. [Figure 2] FIG. 2 is a plan view of a drug volatilization sheet according to another embodiment of the present invention. [Figure 3] FIG. 2 is a cross-sectional view taken along line AA of a chemical volatilization sheet according to one embodiment of the present invention. [Figure 4] FIG. 2 is a cross-sectional view of a drug volatilization sheet taken along line AA in another embodiment of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0013] [Drug volatilization sheet] The drug volatilization sheet of the present invention comprises a drug retention layer containing a drug, and a permeable layer that is provided on one or both sides of the drug retention layer and allows the drug to permeate, the permeable layer having an area that covers the drug retention layer (coated area) and an area that does not cover the drug retention layer (uncoated area), and the coated area contains a photo- or thermosetting resin, (100mm 2 The area of the uncoated area per 2 )) / (thickness of the transmission layer (mm))=80 to 350. Hereinafter, embodiments of the chemical volatilizing sheet of the present invention will be described in detail. Note that when a range is indicated in the description, it includes an upper limit and a lower limit.

[0014] In some embodiments, the transmission layer has areas that cover the drug retention layer (coated areas) and areas that do not cover the drug retention layer (uncoated areas), and can be cured with light or heat to form a pattern as shown in the plan view of Figure 1 or 2. 3 is a cross-sectional view of a drug volatilization sheet according to one embodiment of the present invention. This embodiment is a drug volatilization sheet comprising a drug-containing drug retention layer 1 and permeation layers 2 provided on both sides of the layer. Such a drug volatilization sheet can be used indoors or outdoors, for example, by being held in a holder worn around the user's neck.

[0015] In the embodiment shown in Fig. 4, a drug-containing drug retention layer 1 is provided with a permeation layer 2, which is further provided with a barrier layer 3 and an adhesive layer 4. Such a drug volatilizing sheet can be used indoors or outdoors by, for example, attaching it to the user's skin or clothing so that the adhesive layer 4 abuts against it.

[0016] The "drug" of the present invention is not limited to, but includes, for example, pest control agents such as repellents and insecticides containing a pest repellent component or an insecticidal component together with a solvent; bactericidal and sterilizing agents containing a bactericidal component or a disinfecting component; drugs containing antiviral components; and agents containing aromatic components. The drug may be any agent containing a volatile component.

[0017] The repellent in one embodiment of the present invention is a liquid active ingredient compound that gradually volatilizes at room temperature of about 15 to 40°C in the environment of use and that repels pests such as mosquitoes and horseflies from sucking blood, or a composition containing the compound as one of its components. To ensure that the repellent effect develops over time, it is preferable to use a repellent with a boiling point higher than the room temperature. Pyrethroid compounds, as described below, can also be used as the repellent.

[0018] Such repellents preferably contain essential oils as active ingredients. Specific examples of essential oils include those extracted from grapefruit, geranium, rosemary, anise, armoise, ylang-ylang, orange, cananga, chamomile, cardamom, cajeput, clary sage, clove, coriander, cypress, sandalwood, cedarwood, citronella, juniper berry, ginger, spearmint, sage, tea tree, nutmeg, neroli, pine needle, basil, patchouli, palmarosa, fennel, black pepper, petitgrain, vetiver, peppermint, bergamot, marjoram, mandarin, lemon eucalyptus, eucalyptus, copaiba, lime, lavender, lemon, lemongrass, rosewood, alpinia japonica leaf, cinnamon bark, and peppermint. Essential oils extracted from one of these plants or two or more of these plants can be used in combination.

[0019] The essential oils obtained from the above plants contain various volatile compounds, i.e., essential oil components. Grapefruit contains d-limonene, myrcene, α-pinene, etc. Geranium contains citronellol, geraniol, linalool, etc. Rosemary contains α-pinene, camphor, 1,8-cineole, etc. Anise contains (E)-anethole, limonene, anisaldehyde, etc. Armoise contains 1,8-cineole, thujone, borneol, camphor, pinene, artemisinin (sesquiterpene lactone), linalool, nerol, etc. Ylang-ylang contains linalool, β-potassium olefin, germacrene D, etc. Orange contains limonene, myrcene, β-bisabolene, etc. Cananga contains caryophyllene, geranyl acetate, terpineol, etc. Chamomile contains farnesene, chamazulene, α-bisabolol oxide B, etc. Cardamom contains 1,8-cineole, α-terpinyl acetate, limonene, etc. Cajeput contains 1,8-cineole, α-terpineol, para-cymene, etc. Clary sage contains linalyl acetate, linalool, germacrene D, etc. Cloves contain eugenol, β-caryophyllene, eugenyl acetate, etc. Coriander contains d-linalool, camphor, α-pinene, etc. Cypress contains α-pinene, δ-3-carene, etc. Sandalwood contains cis-α-santalol, cis-β-santalol, epi-β-santalol, etc. Cedarwood contains thujopsene, α-cedrene, cedrol, etc. Citronella contains geraniol, limonene, citronellol, camphene, citronellal, geranyl acetate, α-pinene, α-terpineol, etc. Juniper berries contain α-pinene, myrcene, β-farnesene, etc. Ginger contains ar-curcumene, α-zingiberene, β-sesquiphellandrene, etc.Spearmint contains (-)-carvone, dihydrocarvone, 1,8-cineole, etc. Sage contains alpha-thujone, beta-thujone, camphor, etc. Tea tree contains terpinen-4-ol, gamma-terpinene, alpha-terpinene, etc. Nutmeg contains alpha-pinene, sabinene, beta-pinene, etc. Neroli contains linalool, limonene, beta-pinene, etc. Pine needles contain alpha-pinene, beta-pinene, myrcene, etc. Basil contains linalool, methyl chavicol, beta-caryophyllene, etc. Patchouli contains patchouli alcohol, alpha-patulene, beta-caryophyllene, etc. Palmarosa contains geraniol, geranyl acetate, linalool, etc. Fennel contains (E)-anethole, limonene, methyl chavicol, etc. Black pepper contains β-3-caryophyllene, δ-3-carene, limonene, etc. Petitgrain contains linalyl acetate, linalool, α-terpineol, etc. Vetiver contains vetiverol, vetiven, α-vetibol, etc. Bergamot contains limonene, linalyl acetate, linalool, etc. Marjoram contains terpinen-4-ol, cis-sabinene hydrate, para-cymene, etc. Mandarin contains limonene, γ-terpinene, β-pinene, etc. Lemon eucalyptus contains citronellal, citronellol, citral, etc. Eucalyptus contains 1,8-cineole, α-pinene, limonene, aromadendrene, p-cymene, t-pinocarveol, and globulol. Copaiba contains β-potassium olefin, α-humulene, α-copaene, t-α-bergamottene, germacrene D, cadinene, α-bisabolene, γ-mulolene, β-elemene, and σ-elemene. Lime contains limonene, γ-terpinene, and β-pinene. Lavender contains linalyl acetate, linalool, and (Z)-β-ocimene. Lemon contains limonene, β-pinene, and γ-terpinene.Lemongrass contains geranial, citral, elemol, etc. Rosewood contains linalool, α-terpineol, cis-linalool oxide, etc. Peppermint contains l-menthol, l-menthone, menthofuran, etc. Cinnamon bark contains cinnamaldehyde, t-2-methoxycinnamaldehyde, coumarin, etc. Shell ginger leaves contain 1,8-cineole, terpinen-4-ol, p-cymene, etc. Mint contains l-menthol, l-menthone, menthofuran, etc.

[0020] In one embodiment of the present invention, the insecticide preferably contains, but is not limited to, a pyrethroid compound as an active ingredient. Pyrethroid compounds are insecticidal components contained in pyrethrum and their derivatives, and include both natural products obtained by extraction or other methods from plants and synthetic compounds synthesized by organic synthesis. The use of pyrethroid compounds acts as an active ingredient, exerting a control effect on the nerves of pest insects such as mosquitoes and horseflies, thereby eliminating these pests. Furthermore, similar to repellents, it is preferable to use an insecticide with a boiling point higher than the above-mentioned room temperature in order to exert a control effect over time. The insecticide is either a pyrethroid compound itself or a composition containing the pyrethroid compound as one of its components.

[0021] Specific examples of pyrethroid compounds include natural pyrethroids such as pyrethrin I <(1R,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid (1S)-2-methyl-4-oxo-3-(2Z)-2,4-pentadienyl-2-cyclopenten-1-yl ester>, pyrethrin II <(1R,3R)-3-[(1E)-3-methoxy-2-methyl-3-oxo-1-propenyl]-2,2-dimethylcyclopropanecarboxylic acid (1S)-2-methyl-4-oxo-3-(2Z)-2,4-pentadienyl-2-cyclopenten-1-yl ester>, and cinerin I <( 1R,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid (1S)-3-(2Z)-(2-butenyl)-2-methyl-4-oxo-2-cyclopenten-1-yl ester, cinerin II (1R,3R)-3-[(1E)-3-methoxy-2-methyl-3-oxo-1-propenyl]-2,2-dimethylcyclopropanecarboxylic acid (1S)-3-(2Z)-(2-butenyl)-2-methyl-4-oxo-2-cyclopenten-1-yl ester), jasmolin I (1R,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid (1S)-2-Methyl-4-oxo-3-(2Z)-2-pentenyl-2-cyclopenten-1-yl ester>, Jasmolin II <(1R,3R)-3-[(1E)-3-methoxy-2-methyl-3-oxo-1-propenyl]-2,2-dimethylcyclopropanecarboxylic acid> (1S)-2-methyl-4-oxo-3-(2Z)-2-pentenyl-2-cyclopenten-1-yl ester>, and synthetic pyrethroids such as allethrin I (2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid 2-methyl-4-oxo-3-(2-propenyl)-2-cyclopenten-1-yl ester), allethrin II (3-(3-methoxy-2-methyl-3-oxo-1-propenyl)-2,2-dimethylcyclopropanecarboxylic acid 2-methyl-4-oxo-3-(2-propenyl)-2-cyclopenten-1-yl ester), and phthalthrin (also known asD-Tetramethrin) <(1,3-dioxo-4,5,6,7-tetrahydroisoindolin-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate>, Resmethrin <(5-benzyl-3-furyl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate>, Fenothrin <3-phenoxazole> Cybenzyl 2-dimethyl-3-(methylpropenyl)cyclopropanecarboxylate, permethrin 3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate, cyphenothrin cyano(3-phenoxyphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate, etofenprox 4 -(4-ethoxyphenyl)-4-methyl-1-(3-phenoxyphenyl)-2-oxapentane, metofluthrin <2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropanecarboxylic acid = 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl>, profluthrin <(1R,3R)-2,2-dimethyl-3-[(Z)-1-propenyl]cyclopropanecarboxylic acid = 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl> Preferred are transfluthrin <(1R,3S)-3-[(E)-2,2-dichlorovinyl]-2,2-dimethylcyclopropanecarboxylic acid = 2,3,5,6-tetrafluorobenzyl>, transfluthrin <cyano(4-fluoro-3-phenoxyphenyl)methyl = 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carboxylate>, and empenthrin. Among the above, permethrin, fenothrin, allethrin, phthalthrin, restomethrin, metofluthrin, transfluthrin, profluthrin, and empenthrin are more preferred, with metofluthrin, transfluthrin, profluthrin, and empenthrin being most preferred. The above pyrethroid compounds can be used alone or in combination of two or more.

[0022] Some of the above-mentioned repellents and insecticides may have adverse effects on the human body, such as causing discomfort, vomiting, diarrhea, headache, tinnitus, and other toxic symptoms when users come into contact with them. Therefore, it is particularly technically significant to provide a permeable layer 2, which will be described later, to prevent users from coming into contact with the chemical retention layer impregnated with the repellent or insecticide.

[0023] In addition to the essential oils and pyrethroid compounds that are the active ingredients of the repellents and insecticides, the solvents may include ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, and cyclohexanone; paraffinic hydrocarbons; alcohols such as methanol, ethanol, isopropanol, butanol, hexanol, cyclohexanol, phenoxyethanol, and benzyl alcohol; polyhydric alcohols with two or more hydroxyl groups; or glycol ethers. Paraffinic hydrocarbons are saturated hydrocarbons with linear or branched chains containing approximately 10 to 30 carbon atoms, and multiple types can be used in combination. Furthermore, they dissolve the active ingredients and distribute them evenly throughout the chemical retention layer 1. Polyhydric alcohols have low volatility at room temperature, allowing them to remain in the chemical retention layer 1 for a long time. Furthermore, they dissolve the essential oils and pyrethroid compounds, gradually volatilizing them and prolonging the pest control effect.

[0024] Preferred alcohols include ethanol and isopropyl alcohol. Preferred polyhydric alcohols include propylene glycol, dipropylene glycol, 1,3-butylene glycol, sorbitol, glycerin, diglycerin, polyglycerin, and polyethylene glycol. Preferred ketones include acetone. Although not limited thereto, for example, the solvent may be used alone or in combination of two or more.

[0025] In addition, either the repellent or the insecticide can be contained and held in the drug holding layer 1 alone, or the repellent and the insecticide can be mixed in a predetermined ratio and contained and held in the drug holding layer 1.

[0026] In one embodiment of the present invention, the disinfectant / sterilizing agent containing a disinfecting component or a sterilizing component is not limited, but is preferably chlorine dioxide, ethanol, allyl isothiocyanate, or the like.

[0027] In yet another embodiment of the present invention, the agent containing an antiviral component is preferably, but not limited to, ethanol, glutaraldehyde, chlorine dioxide, iodine, or the like.

[0028] In yet another embodiment of the present invention, the agent containing the aromatic component is not limited, but is preferably a natural essential oil, a synthetic fragrance, or the like.

[0029] The structure of drug retention layer 1 is a base material capable of retaining any drug. Drug retention layer 1 retains the drug in a sheet-like shape with a thickness similar to that of a thin plate or paper. Drug retention layer 1 is formed in a form in which the drug is contained in a material that does not chemically degrade with the drug over time, in order to maintain the effects of the active ingredient of the drug.

[0030] Specifically, the structure of the drug retention layer 1 is preferably a porous material having fine pores capable of retaining repellents or insecticides therein, such as nonwoven fabrics formed from polyethylene or polypropylene, paper, woven fabrics, or porous structures made from synthetic resins or inorganic materials, with the pores communicating with the surface. The method for preparing the drug retention layer 1 is not limited, and it can be prepared, for example, by dripping the drug onto the porous structure or immersing the porous structure in a composition containing the drug under normal or reduced pressure. For example, the drug is filled and retained in the fine pores of the porous structure due to the penetration force of the drug, resulting in a contained state.

[0031] Furthermore, the structure of the drug retention layer 1 has a basis weight of 50 to 1000 g / m 2 The thickness is preferably 100 to 3000 μm, and the basis weight is 60 to 800 g / m 2It is more preferable that the thickness is 150 to 2500 μm. When the basis weight and thickness of the chemical retention layer 1 are within these ranges, the chemical retention layer 1 has pores that are large enough to allow the chemical to volatilize from the chemical retention layer 1 and diffuse to the outside, but moisture such as rain does not penetrate into the minute voids in the chemical retention layer 1, so the pest control effect can be sustained.

[0032] The permeable layer 2 is a layer that is provided on one or both of the drug retention layers 1 and is permeable to the drug. Here, the permeable layer (2) has a region that covers the drug retention layer (1) (coated region) and a region that does not cover the drug retention layer (uncoated region), and it is preferable that the coated region contains a photo- or thermosetting resin and is attached to the drug retention layer 1. It is preferable that the drug permeates (volatilizes, etc.) to the outside from the uncoated region and does not or has little permeation into the photo- or thermosetting resin.

[0033] The coating region includes a photo- or thermosetting resin, such as a photo-curable resin composition containing an acrylic resin, a styrene-acrylate copolymer, and an ethylenically unsaturated compound: A resin composition containing an oligophenylene ether, a maleimide compound, an epoxy resin, a styrene-based elastomer, and a modified polyolefin; or Examples include, but are not limited to, thermosetting resin compositions containing styrene-based elastomers and maleimide compounds, and compositions containing urethane resins.

[0034] The color of the coated region is not limited, but is preferably colorless, transparent, or translucent. When the coated region is colorless, transparent, or translucent, the user can see any letters or marks that may be displayed on the drug retention layer.

[0035] The method for forming the permeable layer of the present invention is not limited to, but includes a method of first applying a resin to the structure of the drug retention layer. For example, the coated region can be formed by dropping a curable resin composition onto the structure of the drug retention layer, printing (screen printing, letterpress printing, intaglio printing, lithographic printing, etc.), applying it through a mask, and then curing it.

[0036] The conditions for heat curing are not particularly limited, but it is preferable to heat at 70 to 100° C. for about 30 to 60 minutes, for example.

[0037] The photocuring conditions are not particularly limited, but it is preferable to cure by irradiating ultraviolet rays from a mercury UV lamp with a dominant wavelength of 365 nm or a metal halide UV lamp with a continuous wavelength of 200 to 400 nm.

[0038] The cured resin can be used to form a wave-shaped, dot-shaped, grid-shaped, or other pattern on one or both sides of the drug retention layer, providing a balanced distribution of coated and uncoated areas. The pattern formed in the coated area is shown in Figure 1 as an example of a dot-shaped pattern, and in Figure 2 as an example of a wave-shaped pattern, but is not limited to these.

[0039] The coated and uncoated areas of the transparent layer 2 are formed in an arbitrary pattern. The area ratio is not limited to, but is preferably 100 mm 2 The ratio is preferably 1:0.3 to 50, more preferably 0.5 to 30 per unit area. The thickness of the permeable layer 2 is not limited, but is preferably 0.2 to 2 mm, more preferably 0.2 to 1.7 mm. By providing the permeable layer 2, the drug in the drug volatilization sheet can be sufficiently volatilized while preventing the user from touching the drug-containing drug retention layer 1. The pattern of the permeable layer 2 is not limited, and any pattern may be used. For example, as shown in FIG. 1, it may be formed in a dotted pattern, with the uncovered areas formed as gaps between the dots. The dots are circular, but in other embodiments, they may be triangular, rectangular, elliptical, oval, semicircular, star-shaped, or other shapes. Furthermore, they may be formed in a wave shape as shown in FIG. 2. They may also be formed in a linear pattern such as vertical or horizontal lines, or in a grid pattern. The thickness of the permeable layer 2 refers to the thickness of the photo- or thermosetting resin in the covered area. If the resin thickness is not uniform, the thickness may be 100 mm. 2 In particular, if the thickness of the permeation layer 2 is within this range, for example, when the drug volatilizing sheet of the present invention is in the form of a patch, the rigidity of the permeation layer 2 can prevent the drug volatilizing sheet of the present invention from peeling off from clothing or the like when it is attached to clothing or the like.

[0040] The chemical volatilization sheet of the present invention is designed to achieve both the effects of good chemical volatilization and prevention of chemical adhesion. 2 Area of uncoated area per unit area (mm 2 )) / (thickness of the permeable layer (mm)) can be in the range of 80 to 350. This ratio is more preferably 90 to 300.

[0041] When the drug volatilizing sheet of the present invention is in the form of a patch, barrier layer 3 is optionally provided on one side of drug retention layer 1 and is a member that is drug impermeable. Like drug retention layer 1, barrier layer 3 is sheet-like and made of a material that does not chemically degrade with the drug over time. By containing or laminating another object via barrier layer 3, the drug impregnated in drug retention layer 1 is prevented from seeping into other objects, such as adhesive layer 4 or clothing attached to adhesive layer 4, and causing physical or chemical degeneration. Specifically, barrier layer 3 is preferably a composite material obtained by vapor-depositing a plastic film with a polyolefin such as polyethylene or polypropylene, polyethylene terephthalate, a metal such as aluminum, aluminum, silica, or alumina. Note that methods such as welding by applying high frequency or heat can be used to integrate barrier layer 3 and drug retention layer 1.

[0042] The adhesive layer 4 is provided on the barrier layer 3 on the opposite side of the drug retention layer 1, and is a member that can be adhered to an object. The adhesive layer 4 can be attached to the user's skin or clothing to prevent damage from pests while outdoors, and to exert a bactericidal effect, and can also be peeled off when no longer needed.

[0043] As the adhesive layer 4, various adhesives can be used, such as an acrylic resin-based adhesive obtained by polymerizing an acrylic monomer, or a urethane resin-based adhesive obtained by the reaction of an isocyanate group with a hydroxy group, and it is preferable to form such an adhesive in the form of a layer on one side surface of the barrier layer 3.

[0044] Figure 3 shows a drug volatilization sheet in which a permeation layer 2 is provided on both sides of a drug retention layer 1, and Figure 4 shows an embodiment in which a permeation layer 2 is provided on one side of the drug retention layer 1 and a barrier layer 3 and an adhesive layer 4 are provided on the other side.

[0045] Although not shown, a release paper layer is preferably provided on the adhesive layer 4 on the side opposite the drug retention layer 1 and the barrier layer 3. The release paper layer prevents the adhesive layer 4 from adhering to unintended objects when unused and prevents dust and other particles from adhering to the adhesive layer 4. The release paper layer is preferably attached to the adhesive layer 4 in advance, such as when the product is collected. The release paper layer may be attached individually to each drug volatilization sheet according to its size, or a single release paper layer may be attached to all of a plurality of drug volatilization sheets. Specifically, the release paper layer preferably has a base material such as high-quality paper or glassine paper, with a silicone resin applied to the surface that contacts the adhesive layer 4.

[0046] [Manufacturing method] The present invention also relates to a method for producing a drug volatilization sheet, which includes a step of forming the permeable layer by applying or printing an ink containing a photo- or thermosetting resin onto a drug retention layer. Printing may be performed by stencil printing, letterpress printing, intaglio printing, or planographic printing, with stencil printing being particularly preferred. For example, a coated region can be formed by dropping a curable resin composition onto the drug retention layer structure, printing (stencil printing, letterpress printing, intaglio printing, planographic printing, etc.), or applying the composition through a mask and curing it. Non-limiting examples of methods for producing a drug volatilization sheet include first applying a resin to a porous structure that forms the drug retention layer structure to form a permeable layer, and then impregnating the porous structure with the formed permeable layer with a drug. The detailed conditions for this manufacturing method are the same as those described in the above section [Drug volatilization sheet]. [Example]

[0047] Next, the present invention will be described in detail with reference to examples, but the present invention is not limited to the following examples. Note that the unit of the amount of each component in the tables is % by mass unless otherwise specified in the tables.

[0048] Examples and Comparative Examples Chemical volatilization sheets of Examples and Comparative Examples having the compositions and structures shown in Table 1 were prepared and subjected to a chemical volatilization test.

[0049] Here, when preparing the chemical volatilization sheet, a porous body with an area of 46.75 cm was used to retain the chemical. 2 A transparent layer (printing layer) was formed on the paper using a stencil printer (product name: silk screen printer; manufactured by Sakurai Graphic Systems Co., Ltd.) with resin ink (product name: Raycure OP 4300-2 Series FG Thick Clear; manufactured by Jujo Chemical Co., Ltd.). Separately, 4 g of transfluthrin was diluted with 20 mL of solvent (acetone) to prepare a solution with a concentration of 0.2 mg / mL.

[0050] After providing the permeable layer, the prepared drug was applied to the paper at a rate of 1.07 mg / cm 2 The sheets thus prepared were subjected to the following tests.

[0051] That is, the permeable layer 2 can be simulated and evaluated as shown below to determine whether it can sufficiently volatilize the drug while preventing the user from coming into contact with the drug-containing drug retention layer.

[0052] [Drug volatility test] The chemical volatilization sheet was evaluated for its chemical volatilization performance. After allowing the active ingredient to volatilize for 24 hours at 25°C, transfluthrin was ultrasonically extracted from the drug-retaining layer with acetone and analyzed by gas chromatography to confirm volatility. Extraction was performed by cutting the sheet into 1cm cubes and ultrasonically extracting with 20mL of acetone for 1 hour. The gas chromatography conditions were as follows: [Analysis conditions] Measurement equipment: Gas chromatograph (product name: GC-2014; manufactured by Shimadzu Corporation) Column HP-FFAP 0.53mm I.D x 10m Column temperature: 170°C Carrier gas: Nitrogen

[0053] As a result, those that volatilized 5 mg or more of the drug were evaluated as ◎, those that volatilized 2 mg or more but less than 5 mg of the drug were evaluated as ○, those that volatilized 0.5 mg or more but less than 2 mg of the drug were evaluated as △, and those that volatilized less than 0.5 mg of the drug were evaluated as ×. Of these, ◎, ○, and △ were evaluated as good, as the drug, especially the active ingredient, was volatilized, and × was evaluated as poor, as the amount of volatilization was significantly low. The thickness of the permeable layer, the uncoated area, and the ratio of the uncoated area to the thickness of the permeable layer are also shown in Table 1.

[0054] [Table 1]

[0055] Examples and Comparative Examples Chemical volatilizing sheets of Examples and Comparative Examples having the compositions and structures shown in Table 2 were prepared and subjected to a non-contact test.

[0056] [Non-contact test] Here, when preparing the chemical volatilization sheet, a porous material with an area of 7.0 cm was used to retain the chemical. 2 A 0.3 mm thick paper was used. A transparent layer (printing layer) was formed on the paper as a dot pattern using stencil printing with a resin ink (product name: Raycure OP 4300-2 Series FG Thick Clear; manufactured by Jujo Chemical Co., Ltd.). Separately, black ink was prepared to resemble a drug.

[0057] After forming the permeable layer, 50 mg of the prepared black ink was applied to the paper, and any remaining ink was washed off with IPA and allowed to dry for approximately 5 minutes. A 1 cm square piece of urethane was placed on top and pressed down from above. The pressing force was measured using a scale at 300 g and 500 g. The colored area and adhesion of the ink were visually confirmed. As a result, a case in which no black ink was attached to the urethane was evaluated as ◎, a case in which almost no black ink was attached to the urethane was evaluated as ○, a case in which some black ink was attached to the urethane was evaluated as △, and a case in which considerable black ink was attached to the urethane was evaluated as ×. Of these, ◎ and ○, indicating that almost no black ink was attached, were judged as good, and △ and ×, indicating that some black ink was attached, were judged as bad. The results of the non-contact test are shown in Table 2.

[0058] [Table 2]

[0059] As shown in Tables 1 and 2, the drug volatilization sheets of the examples were found to be able to achieve the contradictory effects of volatilizing the drug while leaving the black ink representing the drug largely unattached. This indicates that, if the permeable layer has a predetermined ratio of the area of the coated area to the thickness of the permeable layer, the drug volatilization sheet equipped therewith can sufficiently volatilize the drug while preventing the user from coming into contact with the drug-containing drug retention layer. On the other hand, none of the drug volatilization sheets of the comparative examples were able to achieve both volatility and adhesion. [Explanation of symbols]

[0060] 1. Drug retention layer 2...Transparent layer 3. Barrier layer 4. Adhesive layer 5. Photo- or thermosetting resin

Claims

1. A drug volatilization sheet comprising a drug retention layer containing a drug, and a permeable layer provided on one or both sides of the drug retention layer and allowing the drug to permeate, the permeable layer having an area that covers the drug retention layer and an area that does not cover the drug retention layer, and the covered area contains a photo- or thermosetting resin, (100 mm ２ The area of the uncoated area per mm ２ )) / (thickness of the permeable layer (mm)) = 80 to 350.

2. The drug volatilizing sheet according to claim 1, wherein the thickness of the permeable layer is 0.2 to 2 mm.

3. A drug-evaporating sheet as described in claim 1 or 2, wherein the coated areas of the permeable layer form an arbitrary pattern together with the uncoated areas, and the ratio of the uncoated areas to the coated areas is 1:0.3 to 50.

4. A method for producing a drug volatilizing sheet according to any one of claims 1 to 3, A manufacturing method comprising the step of forming the transmission layer by printing an ink containing a photo- or thermosetting resin on the drug retention layer.

Images